These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

806 related articles for article (PubMed ID: 23547840)

  • 81. Pre-transplant MRD predicts outcome following reduced-intensity and myeloablative allogeneic hemopoietic SCT in AML.
    Anthias C; Dignan FL; Morilla R; Morilla A; Ethell ME; Potter MN; Shaw BE
    Bone Marrow Transplant; 2014 May; 49(5):679-83. PubMed ID: 24510069
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Comparison of Multiparameter Flow Cytometry Immunophenotypic Analysis and Quantitative RT-PCR for the Detection of Minimal Residual Disease of Core Binding Factor Acute Myeloid Leukemia.
    Ouyang J; Goswami M; Peng J; Zuo Z; Daver N; Borthakur G; Tang G; Medeiros LJ; Jorgensen JL; Ravandi F; Wang SA
    Am J Clin Pathol; 2016 Jun; 145(6):769-77. PubMed ID: 27298396
    [TBL] [Abstract][Full Text] [Related]  

  • 83. The Role of Measurable Residual Disease (MRD) in Hematopoietic Stem Cell Transplantation for Hematological Malignancies Focusing on Acute Leukemia.
    Czyz A; Nagler A
    Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31661875
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Prevention of relapse in pediatric patients with acute leukemias and MDS after allogeneic SCT by early immunotherapy initiated on the basis of increasing mixed chimerism: a single center experience of 12 children.
    Bader P; Klingebiel T; Schaudt A; Theurer-Mainka U; Handgretinger R; Lang P; Niethammer D; Beck JF
    Leukemia; 1999 Dec; 13(12):2079-86. PubMed ID: 10602432
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Early Post-Transplant Minimal Residual Disease Assessment Improves Risk Stratification in Acute Myeloid Leukemia.
    Shah MV; Jorgensen JL; Saliba RM; Wang SA; Alousi AM; Andersson BS; Bashir Q; Ciurea SO; Kebriaei P; Marin D; Patel KP; Popat UR; Rezvani K; Rondon G; Shpall EJ; Champlin RE; Oran B
    Biol Blood Marrow Transplant; 2018 Jul; 24(7):1514-1520. PubMed ID: 29448058
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Predictive factors of relapse and survival in childhood acute myeloid leukemia: role of minimal residual disease.
    Rizzari C; Cazzaniga G; Coliva T; De Angelis C; Conter V
    Expert Rev Anticancer Ther; 2011 Sep; 11(9):1391-401. PubMed ID: 21929313
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Comparison of Autologous Stem Cell Transplantation versus Haploidentical Donor Stem Cell Transplantation for Favorable- and Intermediate-Risk Acute Myeloid Leukemia Patients in First Complete Remission.
    Chen J; Yang L; Fan Y; Xu Y; Han Y; Tang X; Qiu H; Fu C; Miao M; Chen F; Wu D
    Biol Blood Marrow Transplant; 2018 Apr; 24(4):779-788. PubMed ID: 29289758
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Efficacy of myeloablative allogeneic hematopoietic stem cell transplantation in adult patients with MLL-ELL-positive acute myeloid leukemia.
    Muto T; Takeuchi M; Yamazaki A; Sugita Y; Tsukamoto S; Sakai S; Takeda Y; Mimura N; Ohwada C; Sakaida E; Aotsuka N; Iseki T; Nakaseko C
    Int J Hematol; 2015 Jul; 102(1):86-92. PubMed ID: 25758097
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Treatment of high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: final results of the PETHEMA ALL-AR-03 trial.
    Ribera JM; Oriol A; Morgades M; Montesinos P; Sarrà J; González-Campos J; Brunet S; Tormo M; Fernández-Abellán P; Guàrdia R; Bernal MT; Esteve J; Barba P; Moreno MJ; Bermúdez A; Cladera A; Escoda L; García-Boyero R; Del Potro E; Bergua J; Amigo ML; Grande C; Rabuñal MJ; Hernández-Rivas JM; Feliu E
    J Clin Oncol; 2014 May; 32(15):1595-604. PubMed ID: 24752047
    [TBL] [Abstract][Full Text] [Related]  

  • 90. CD25 expression on residual leukemic blasts at the time of allogeneic hematopoietic stem cell transplant predicts relapse in patients with acute myeloid leukemia without complete remission.
    Ikegawa S; Doki N; Kurosawa S; Yamaguchi T; Sakaguchi M; Harada K; Yamamoto K; Hino Y; Shingai N; Senoo Y; Hattori K; Igarashi A; Najima Y; Kobayashi T; Kakihana K; Sakamaki H; Haraguchi K; Okuyama Y; Ohashi K
    Leuk Lymphoma; 2016; 57(6):1375-81. PubMed ID: 26422713
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Clinical Utility of Wilms' Tumor 1 Monitoring in Patients with Myeloid Malignancy and Prior Allogeneic Hematopoietic Stem Cell Transplantation.
    Ino K; Fuji S; Tajima K; Tanaka T; Okinaka K; Inamoto Y; Kurosawa S; Kim SW; Katayama N; Fukuda T
    Biol Blood Marrow Transplant; 2017 Oct; 23(10):1780-1787. PubMed ID: 28673850
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Improved minimal residual disease detection by targeted quantitative polymerase chain reaction in Nucleophosmin 1 type a mutated acute myeloid leukemia.
    Pettersson L; Levéen P; Axler O; Dvorakova D; Juliusson G; Ehinger M
    Genes Chromosomes Cancer; 2016 Oct; 55(10):750-66. PubMed ID: 27191933
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Measurable residual disease monitoring by ddPCR in the early posttransplant period complements the traditional MFC method to predict relapse after HSCT in AML/MDS: a multicenter retrospective study.
    Chen W; Huang J; Zhao Y; Huang L; Yuan Z; Gu M; Xu X; Shi J; Luo Y; Yu J; Lai X; Liu L; Fu H; Bao C; Huang X; Zheng Z; Huang H; Hu X; Zhao Y
    J Transl Med; 2024 Apr; 22(1):410. PubMed ID: 38689269
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Monitoring of minimal residual disease after allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia allows for the identification of impending relapse: results of the ALL-BFM-SCT 2003 trial.
    Bader P; Kreyenberg H; von Stackelberg A; Eckert C; Salzmann-Manrique E; Meisel R; Poetschger U; Stachel D; Schrappe M; Alten J; Schrauder A; Schulz A; Lang P; Müller I; Albert MH; Willasch AM; Klingebiel TE; Peters C
    J Clin Oncol; 2015 Apr; 33(11):1275-84. PubMed ID: 25605857
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Wilms' tumor gene 1 expression analysis by real-time quantitative polymerase chain reaction for monitoring of minimal residual disease in acute leukemia.
    Nowakowska-Kopera A; Sacha T; Florek I; Zawada M; Czekalska S; Skotnicki AB
    Leuk Lymphoma; 2009 Aug; 50(8):1326-32. PubMed ID: 19811333
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Detectable minimal residual disease before allogeneic hematopoietic stem cell transplantation predicts extremely poor prognosis in children with acute lymphoblastic leukemia.
    Sramkova L; Muzikova K; Fronkova E; Krejci O; Sedlacek P; Formankova R; Mejstrikova E; Stary J; Trka J
    Pediatr Blood Cancer; 2007 Jan; 48(1):93-100. PubMed ID: 16521130
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Haploidentical allograft is superior to matched sibling donor allograft in eradicating pre-transplantation minimal residual disease of AML patients as determined by multiparameter flow cytometry: a retrospective and prospective analysis.
    Chang YJ; Wang Y; Liu YR; Xu LP; Zhang XH; Chen H; Chen YH; Wang FR; Han W; Sun YQ; Yan CH; Tang FF; Mo XD; Liu KY; Huang XJ
    J Hematol Oncol; 2017 Jul; 10(1):134. PubMed ID: 28676064
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Minimal residual disease markers before and after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia.
    Dominietto A
    Curr Opin Hematol; 2011 Nov; 18(6):381-7. PubMed ID: 21986564
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Pre- and post-transplant minimal residual disease predicts relapse occurrence in children with acute lymphoblastic leukaemia.
    Lovisa F; Zecca M; Rossi B; Campeggio M; Magrin E; Giarin E; Buldini B; Songia S; Cazzaniga G; Mina T; Acquafredda G; Quarello P; Locatelli F; Fagioli F; Basso G
    Br J Haematol; 2018 Mar; 180(5):680-693. PubMed ID: 29359790
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Introducing minimal residual disease in acute myeloid leukemia.
    Ofran Y; Rowe JM
    Curr Opin Hematol; 2015 Mar; 22(2):139-45. PubMed ID: 25575038
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 41.